Development
Clover Biopharmaceuticals' SCB-1019 shows positive Phase I RSV re-vaccination data in older adults
Clover Biopharmaceuticals (HKEX: 02197), a Shanghai-based biotechnology company, reported additional Phase I data for its RSV prefusion F protein vaccine...
Basilea's BAL2420 enters the clinic as first-in-class LptA inhibitor targeting Gram-negative resistance
Basilea Pharmaceutica, the Swiss commercial-stage anti-infectives company, has dosed the first healthy volunteer in a phase 1 study of the BAL2420...
Apogee Therapeutics' zumilokibart maintains atopic dermatitis responses with every-three-to-six-month dosing in Phase II trial
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotech based in San Francisco and Boston, reported 52-week maintenance data from the Phase II APEX...
Kainova Therapeutics' DT-9081 shows early promise in Phase I advanced solid tumors trial
Montreal-based Kainova Therapeutics announced topline results from its Phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, in patients with...
Skye Bioscience Nimacimab and Semaglutide Combination Demonstrates 22.3% Weight Loss in Phase 2a Trial
Skye Bioscience [announced](https://www.globenewswire.com/news-release/2026/02/02/3230132/0/en/Skye-Reports-Positive-CBeyond-Phase-2a-Extension-Interim-Study-Results-for-Nimacimab-in-Combination-With-Semaglutide.html) positive clinical trial results for nimacimab, a peripherally-restricted CB1 inhibitor antibody, when combined with semaglutide in treating obesity. The Phase 2a CBeyond study demons
Evorpacept Plus Zanidatamab Shows Promise in Phase 2 HER2+ Metastatic Breast Cancer Trial
ALX Oncology has unveiled promising positive clinical trials data for its investigational CD47 inhibitor evorpacept, demonstrating potential breakthrough therapeutic approaches in advanced HER2-positive metastatic breast cancer. The Phase 1b/2 clinical trial exploring evorpacept's combination with zanidatamab revealed intriguing insights into targeted cancer treatment strategies, highlighting the
HDM2006: First-in-Human Phase 1 Trial Explores HPK1 Inhibition in Advanced Solid Tumors
Researchers at Fudan University Shanghai Cancer Center have initiated a first-in-human clinical trial investigating HDM2006, an experimental drug targeting the Hematopoietic Progenitor Kinase 1 (HPK1) pathway in patients with advanced solid tumors. The [Phase 1 study](https://clinicaltrials.gov/study/NCT07377591) represents a critical early step in evaluating the safety, tolerability, and potentia
OMEICOS' OMT-28 Shows Promise in Phase 2a Trial for Primary Mitochondrial Diseases
OMEICOS Advances Mitochondrial Disease Therapy with Promising Phase 2a Results OMEICOS Therapeutics ...
TPD3310: First-in-Human Phase I Trial Targeting c-MET Protein Degradation in Solid Tumors
Novel c-MET Degrader Enters First-in-Human Trial for Advanced Solid Tumors Researchers have initiat...
SPR1020: First-in-Human Phase I Trial Explores Highly Selective PARP1 Inhibitor Potential
A first-in-human clinical trial for SPR1020, a novel highly selective PARP1 inhibitor targeting advanced solid tumors, is set to begin, marking a potentially significant advance in precision oncology therapeutics. The phase I trial will evaluate the safety, tolerability, and preliminary efficacy of this new molecular entity designed to overcome limitations of current PARP inhibition strategies.
Shanghai Xianwei's SIM0610: First-in-Human Phase 1 Trial for Advanced Solid Tumors
Novel Cancer Therapeutic SIM0610 Enters First-in-Human Trial Shanghai Xianwei Medical Technology Co...
Veltischev Institute Launches First-in-Human ASO-GNAO1 Trial for Rare Neurological Disorder
Personalized Antisense Therapy Offers New Hope for Rare Neurological Disorder Researchers are launch...
Adcendo's ADCE-B05 ADC Enters Phase 1a/1b Trial for Advanced Solid Tumor Treatment
Novel Antibody-Drug Conjugate Enters First-in-Human Trial for Advanced Solid Tumors Adcendo ApS is a...
SWA1211 HPK1 Inhibitor Enters First-in-Human Phase I Trial for Advanced Solid Tumors
Novel HPK1 Inhibitor Enters First-in-Human Trial for Advanced Solid Tumors Researchers have initiat...
STEAP2-Targeted CAR-T Therapy Enters Phase 1 Trial for Metastatic Prostate Cancer
Novel CAR-T Approach Targets Prostate Cancer's Elusive Molecular Landscape Researche...
The AllSci Brief
Systematic R&D and deal news. Daily.